Showing 3711-3720 of 5773 results for "".
- Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Diseasehttps://modernod.com/news/tarsus-initiates-phase-2a-ersa-trial-evaluating-tp-03-for-the-treatment-of-meibomian-gland-disease/2481015/Tarsus Pharmaceuticals announced that it has enrolled the first patient in a phase 2a clinical trial studying TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of meibomian gland disease (MGD) in patients with Demodex mites. Demodex
- Glaukos Receives FDA 510(k) Clearance of the iStent Infinitehttps://modernod.com/news/glaukos-receives-fda-510k-clearance-for-the-istent-infinite/2481013/Glaukos announced that it has received 510(k) clearance from the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is indicated for use in a standalone procedure to reduce elevated IOP in patients with primary open-angle glaucoma uncontrolled
- FDA Approves First Biosimilar Interchangeable to Lucentishttps://modernod.com/news/fda-approves-fyb201cimerli-the-first-and-only-biosimilar-to-lucentis/2481012/Coherus BioSciences announced that the FDA has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), d
- Ocuphire Extends US Patent Protection for Drug Candidate Nyxol for Reversal of Mydriasis by 5 More Years Into 2039https://modernod.com/news/ocuphire-extends-us-patent-protection-for-drug-candidate-nyxol-for-reversal-of-mydriasis-by-5-more-years-into-2039/2481011/Ocuphire Pharma announced the issuance of a new U.S. Patent (No. 11,400,077), which provides added intellectual property protection for the company’s late-stage product candidate, Nyxol (phentolamine mesylate), with claims directed to methods for treating mydriasis using phentolamine m
- LumiThera Purchases MacuLogix Assetshttps://modernod.com/news/lumithera-purchases-maculogix-assets/2481007/LumiThera announced the purchase of the assets of MacuLogix. Terms of the deal were not disclosed. MacuLogix is the developer of the wearable AdaptDX Pro dark adaptometer, which allows eye care professionals to measure dark adaptation—designed to dia
- Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the UShttps://modernod.com/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us/2481003/Dr. Reddy’s Laboratories, along with its subsidiaries, announced it has entered into a licensing agreement with Princeton, New Jersey-based Slayback Pharma to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify
- Lenstec Receives FDA Approval for the SBL-3 Multifocal IOLhttps://modernod.com/news/lenstec-receives-fda-approval-for-sbl-3-multifocal-iol/2481002/Lenstec Announced that its SBL-3 IOL has been approved by the FDA. The SBL-3 IOL (Segmented Bifocal Lens) is a next-generation asymmetric multifocal refractive IOL that provides patients with near, intermediate and distance vision. Its patented design allows for improved contrast sensit
- Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directorshttps://modernod.com/news/nicox-appoints-jean-francois-labbe-as-chairman-of-the-board-of-directors/2481001/Nicox announced that Jean-Francois Labbé, a board member of Nicox SA, has been appointed as Chairman of the Nicox Board of Directors, effective July 28, 2022. Michele Garufi, who has filled the role ad interim since June 1, 2022, will remain as a Board member. “I am ta
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- LKC Appoints New Members of Sales and Marketing Leadershiphttps://modernod.com/news/lkc-appoints-new-members-of-sales-and-marketing-leadership/2480999/LKC Technologies, a provider of electroretinography devices, announced the hiring of two industry professionals to lead their strategic efforts to expand its foothold in the US optometric market. Gary VanMatre was appointed Vice President, US Sales, and will lead a geographica